▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Lonza Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $60.68.
The current consensus among 6 polled investment analysts is to buy stock in Lonza Group. This rating has held steady since June 2020, when it changed from a Hold consensus rating.
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment operates microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segments also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agro chemicals, and diversified specialty chemicals markets. The company has collaboration with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.